Glaxosmithkline Pharma Q2FY18 standalone net profit rises 30.1%

India Infoline Research Team | October 25, 2017 14:53 IST

Glaxosmithkline Pharma Ltd Q2FY18

Standalone Results Q2FY18: (Rs. in crore)

Q2FY18 YoY (%)
Revenue 836.3 4.7
EBITDA 199.8 35.6
EBITDA Margin (%) 23.9 546
Net Profit (adjusted) 128.5 30.1
***EBITDA margin change is bps
View

Accumulate

Reco. Price

2437.7

Last updated on

24-Oct-2017




Glaxosmithkline Pharmaceuticals Ltd standalone revenue for the quarter came in at Rs. 836.3 crore, registering 4.7% yoy increase.

EBITDA for the quarter rose by 35.6% yoy to Rs. 199.8 crore with a corresponding margin expansion of 546 bps. EBITDA margin for the quarter stood at 23.9%. This margin expansion was aided by 27.2% yoy decline in cost of raw material consumed.

The PAT for the quarter came in at Rs. 128.5 crore, yoy increase of 30.1%.

Company reported exceptional gain of Rs.5.16 crore which relates to profit on sale of property.


Technical View:

Glaxosmithkline Pharmaceuticals Ltd is currently trading at Rs. 2,403.80, down by 43.2 points or 1.77% from its previous closing of Rs. 2,447 on the BSE.
The scrip opened at Rs. 2,454.90 and has touched a high and low of Rs. 2,460 and Rs. 2,381.10 respectively. So far 37,079(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 200 DMA.

BSE 2,370.55 [25.85] ([1.08]%)
NSE 2,369.10 [29.50] ([1.23]%)

***Note: This is a NSE Chart

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.